December 27, 2014 4:05 PM ET

Healthcare Equipment and Supplies

Company Overview of Auxogyn, Inc.

Company Overview

Auxogyn, Inc. develops solutions for women’s reproductive health applications. The company’s product is a non-invasive early embryo viability assessment system (Eeva), which provides quantitative information regarding embryo development to assist in vitro fertilization (IVF) clinics in selecting the best embryo(s) for transfer and optimizing the treatment path for their patients undergoing IVF procedures. Auxogyn, Inc. was incorporated in 2008 and is based in Menlo Park, California.

1490 O’Brien Drive

Suite A

Menlo Park, CA 94025

United States

Founded in 2008

Phone:

650-641-2429

Fax:

650-325-2094

Key Executives for Auxogyn, Inc.

Co-Founder
Age: 58
Chief Operating Officer
Age: 48
Head of Biomedical Research
Vice President of Clinical Research and Development
Vice President of Commercial Development
Compensation as of Fiscal Year 2014.

Auxogyn, Inc. Key Developments

Auxogyn, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 09:10 AM

Auxogyn, Inc. Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 09:10 AM. Venue: Le Parker Meridien, New York, New York, United States.

Auxogyn, Inc. Receives FDA Clearance for its Eeva(TM) System

Auxogyn, Inc. announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind. The Eeva System enables in vitro fertilization (IVF) clinicians to offer the proprietary Eeva Test, which is the first prognostic, non-invasive test that provides objective information regarding embryo development to help optimize treatment plans for their patients.

Merck Serono S.A. Signs License Agreement with Auxogyn, Inc. for Auxogyn's Proprietary Early Embryo Viability Assessment Test

Merck Serono S.A. has signed an exclusive license agreement with Auxogyn, Inc. for Auxogyn's proprietary Early Embryo Viability Assessment test. The Eeva Test is a non-invasive diagnostic test used adjunctively to traditional morphology. Under the terms of the agreement, Merck Serono will obtain exclusive rights to commercialize the Eeva Test in Europe and Canada, with the option to extend to selected countries and regions.

Similar Private Companies By Industry

Company Name Region
Phi Health, LP United States
Ideal Instruments, Inc. United States
Med-Dispense, L.P. United States
CerMed International, Inc. United States
Synapse Biomedical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Auxogyn, Inc., please visit www.auxogyn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.